BioArctic Partner Eisai Presents Real-World Lecanemab Data At AD/PD 2026 Showing 78.4% Of Early Alzheimer's Patients Continued Treatment At 18 Months - Bioage Labs (NASDAQ:BIOA), Eisai Co (OTC:ESAIY)
Published on March 23, 2026.
The Real-World Lecanemab Data, presented at the AD/PD 2026, shows that 78.4% of early Alzheimer's patients continue their treatment at the age of 18 months. The data also highlights the effectiveness of the drug in the body of the pharmaceutical industry.
Related Articles
5 hidden ‘sleep stealers’ in your bedroom — and an addition that ‘goes a long way’
A mattress that's too firm, a thermostat set too cold, and light and other intruders in your bedroom contribute to sleep deprivation, leading to inconsistent sleep patterns.
Insights Into Apple's Performance Versus Peers In Technology Hardware, Storage & Peripherals Sector - Apple (NASDAQ:AAPL)
A comprehensive analysis of Apple's financial performance reveals mixed results, with high debt, profitability, and potential undervaluation.
Deadline shock rattles global markets
Global stock market plummeting due to President Trump's deadline for reopening the Strait of Hormuz, prompting concerns over safety and effectiveness among investors.